Cytokinetics, Incorporated
Cytokinetics, Incorporated（CYTK）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · CYTK · 截至 2026年6月8日
活动摘要
买入笔数
0
P-Purchase only
卖出笔数
77
近12个月
买卖比
0.00
Buy/Sell (by trades)
整体情绪
Cytokinetics, Incorporated内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
CYTK 季度内部人买卖趋势
CYTK 内幕交易卖出 · CYTK 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · CYTK CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
CYTK 高管卖出股份 · CYTK 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Jun 1, 2026 | Kaye Edward M. MD Director | Sale | 2,933 | $223K | Form 4 |
| Jun 1, 2026 | Callos Andrew EVP, Chief Commercial Officer | Option | 15,000 | $349K | Form 4 |
| Jun 1, 2026 | Callos Andrew EVP, Chief Commercial Officer | Sale | 15,000 | $1.11M⚡ | Form 4 |
| Jun 1, 2026 | PARSHALL B LYNNE Director | Sale | 5,000 | $370K | Form 4 |
| May 27, 2026 | Blum Robert I President & CEO · Director | Sale | 7,500 | $579K | Form 4 |
| May 27, 2026 | Bhanji Muna Director | Award | 2,851 | — | Form 4 |
| May 27, 2026 | Daly James M Director | Award | 2,851 | — | Form 4 |
| May 27, 2026 | Harrington Robert Arthur Director | Award | 2,851 | — | Form 4 |
| May 27, 2026 | HENDERSON JOHN T Director | Award | 2,851 | — | Form 4 |
| May 27, 2026 | Kaye Edward M. MD Director | Award | 2,851 | — | Form 4 |
| May 27, 2026 | PARSHALL B LYNNE Director | Award | 2,851 | — | Form 4 |
| May 27, 2026 | Landry Robert E Director | Award | 2,851 | — | Form 4 |
| May 27, 2026 | WIERENGA WENDELL Director | Award | 2,851 | — | Form 4 |
| May 27, 2026 | Wysenski Nancy Director | Award | 2,851 | — | Form 4 |
| May 19, 2026 | Malik Fady Ibraham EVP Research & Development | Option | 3,500 | $27K | Form 4 |
| May 19, 2026 | Malik Fady Ibraham EVP Research & Development | Sale | 3,500 | $265K | Form 4 |
| May 14, 2026 | Blum Robert I President & CEO · Director | Sale | 7,500 | $584K | Form 4 |
| May 5, 2026 | Malik Fady Ibraham EVP Research & Development | Option | 3,500 | $27K | Form 4 |
| May 5, 2026 | Malik Fady Ibraham EVP Research & Development | Sale | 3,500 | $271K | Form 4 |
| May 5, 2026 | WIERENGA WENDELL Director | Option | 4,032 | $50K | Form 4 |
| May 5, 2026 | WIERENGA WENDELL Director | Sale | 4,032 | $302K | Form 4 |
| May 5, 2026 | Lee Sung EVP, Chief Financial Officer | Sale | 23,906 | $1.84M⚡ | Form 4 |
| May 5, 2026 | HENDERSON JOHN T Director | Option | 20,000 | $152K | Form 4 |
| May 5, 2026 | HENDERSON JOHN T Director | Sale | 20,000 | $1.52M⚡ | Form 4 |
| May 5, 2026 | Callos Andrew EVP, Chief Commercial Officer | Option | 11,333 | $443K | Form 4 |
Callos Andrew
EVP, Chief Commercial Officer
日期
Jun 1
股数
15,000
均价
$23.26
总金额
$349K
Callos Andrew
EVP, Chief Commercial Officer
日期
Jun 1
股数
15,000
均价
$74.08
总金额
$1.11M ⚡
Malik Fady Ibraham
EVP Research & Development
日期
May 19
股数
3,500
均价
$7.80
总金额
$27K
Malik Fady Ibraham
EVP Research & Development
日期
May 19
股数
3,500
均价
$75.69
总金额
$265K
Malik Fady Ibraham
EVP Research & Development
日期
May 5
股数
3,500
均价
$7.80
总金额
$27K
Malik Fady Ibraham
EVP Research & Development
日期
May 5
股数
3,500
均价
$77.37
总金额
$271K
Callos Andrew
EVP, Chief Commercial Officer
日期
May 5
股数
11,333
均价
$39.13
总金额
$443K
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 CYTK 内幕交易
CYTK 内幕交易
Cytokinetics, Incorporated（CYTK）内幕交易数据来源于公司内部人（包括Callos Andrew (EVP, Chief Commercial Officer), Malik Fady Ibraham (EVP Research & Development), Blum Robert I (President & CEO · Director)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。CYTK内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Cytokinetics, Incorporated机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
CYTK 内幕交易 · 5个问题Cytokinetics, Incorporated（CYTK）的内部人包括高管和董事，如Callos Andrew (EVP, Chief Commercial Officer), Malik Fady Ibraham (EVP Research & Development), Blum Robert I (President & CEO · Director)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026